Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Thalomid thalidomide: Phase II data; marketed to treat cutaneous manifestations of erythema nodosum leprosum (ENL)

In a 169-patient Phase II trial, 30 percent of patients

Read the full 107 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE